GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » Sale Of Business

Lexaria Bioscience (Lexaria Bioscience) Sale Of Business : $0.00 Mil (TTM As of Feb. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience Sale Of Business?

Lexaria Bioscience's sale of business for the three months ended in Feb. 2024 was $0.00 Mil. It means Lexaria Bioscience gained $0.00 Mil from selling business. Lexaria Bioscience's sale of business for the trailing twelve months (TTM) ended in Feb. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Nov. 2023 ), Lexaria Bioscience gained the same money from selling business in Feb. 2024 ($0.00 Mil).


Lexaria Bioscience Sale Of Business Historical Data

The historical data trend for Lexaria Bioscience's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Sale Of Business Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lexaria Bioscience Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexaria Bioscience Sale Of Business Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Traded in Other Exchanges
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Lexaria Bioscience (Lexaria Bioscience) Headlines

From GuruFocus

Lexaria is Receiving Four New Patents

By ACCESSWIRE ACCESSWIRE 04-20-2023

Lexaria Granted Two New Patents in Canada

By ACCESSWIRE 10-12-2023

Lexaria Appoints New Chief Financial Officer

By ACCESSWIRE ACCESSWIRE 06-12-2023

Lexaria Announces 2023 Annual Meeting Results

By ACCESSWIRE ACCESSWIRE 05-10-2023

Lexaria Releases Annual Letter from the CEO

By ACCESSWIRE 01-24-2024

Lexaria Receives New Patents

By ACCESSWIRE ACCESSWIRE 06-20-2023